BDMARDs targeting tumor necrosis factor alpha (TNFα) were the first to be approved for the treatment of RA, followed by bDMARDs targeting interleukin (IL)-1beta or the IL-6 receptor. The gene discussed is TNF; the disease is rheumatoid arthritis.